Human Vγ9Vδ2 T cells respond to microbial infections as well as certain types of tumors. The key initiators of Vγ9Vδ2 activation are small, pyrophosphate-containing molecules called phosphoantigens (pAgs) that are present in infected cells or accumulate intracellularly in certain tumor cells. Recent studies demonstrate that initiation of the Vγ9Vδ2 T cell response begins with sensing of pAg via the intracellular domain of the butyrophilin 3A1 (BTN3A1) molecule. However, it is unknown how downstream events can ultimately lead to T cell activation. Here, using NMR spectrometry and molecular dynamics (MD) simulations, we characterize a global conformational change in the B30.2 intracellular domain of BTN3A1 induced by pAg binding. We also reveal by crystallography two distinct dimer interfaces in the BTN3A1 full-length intracellular domain, which are stable in MD simulations. These interfaces lie in close proximity to the pAg-binding pocket and contain clusters of residues that experience major changes of chemical environment upon pAg binding. This suggests that pAg binding disrupts a preexisting conformation of the BTN3A1 intracellular domain. Using a combination of biochemical, structural, and cellular approaches we demonstrate that the extracellular domains of BTN3A1 adopt a V-shaped conformation at rest, and that locking them in this resting conformation without perturbing their membrane reorganization properties diminishes pAg-induced T cell activation. Based on these results, we propose a model in which a conformational change in BTN3A1 is a key event of pAg sensing that ultimately leads to T cell activation.
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human Vγ9Vδ2 T cells | butyrophilin 3A1 | phosphoantigen | conformational change G amma delta (γδ) T cells exhibit restricted T cell receptor (TCR) use and tissue-specific residence, and they play critical roles in immune responses to infection and tumorigenesis. In human peripheral blood, a major γδ T cell subset is called Vγ9Vδ2, based on the variable gene segments (TRGV9 and TRDV2) used in the recombined TCR. This population can be activated and expanded to about 50% of total blood T cells upon infection with certain microbes, including the bacterial pathogens Mycobacterium tuberculosis and Mycobacterium leprae and protozoal parasites such as Plasmodium falciparum (1) . Vγ9Vδ2 T cells can quickly launch specific and effective immune responses toward these pathogens (1) . Moreover, they show similar reactivity toward certain types of cancer cells, resulting in widening and intensifying interest in the use of gamma delta T cells for cancer immunotherapy (2) . However, despite intensive research over the past 30 y, the molecular mechanisms governing Vγ9Vδ2 T cells' recognition of infected and malignant cells are still poorly understood, thus impeding the overall understanding of Vγ9Vδ2 T cell immunity and development of its potential medical applications.
Vγ9Vδ2 T cells are specifically activated by a set of pyrophosphate metabolites collectively named phosphoantigens (pAgs), which are present in both infected and malignant target cells (3) . These pAgs are sensed by the butyrophilin 3A1 (BTN3A1) protein, a member of the BTN3A family with three different isoforms (A1, A2, and A3) that confer pAg-mediated reactivity toward target cells by Vγ9Vδ2 T cells (4) . Unrelated to MHC molecules, BTN3A proteins are type-I membrane proteins with two Ig-like extracellular domains with structural homology to the B7 superfamily of proteins (5) . The antibody 20.1, specific to the BTN3A extracellular domains, is capable of activating Vγ9Vδ2 T cells even in the absence of pAgs (4, 5) . Previous structural studies on the BTN3A Ig-like extracellular domains and their complex with 20.1 showed two possible conformations of extracellular domains: a "V-shaped" form, which is compatible with 20.1 binding and has the potential to oligomerize, and a "head-to-tail" form, of which the dimer interface overlaps with the 20.1 binding site (6) . However, it is unknown whether these two dimer forms exist in the full-length BTN3A molecule in the cellular environment, and whether they play a role in pAginduced T cell activation.
While it is still unclear how the extracellular domains of BTN3A contribute to T cell activation, the intracellular B30.2 domain of BTN3A1 has been proven to play a critical role in pAg detection Significance Gamma delta T cells, a group of immune cells that exhibit features from both innate and adaptive immunity, possess significant potential in clinical applications such as treatment of microbial infections and cancer immunotherapy. To fully understand their biology and harness them in the clinic it is imperative to dissect the molecular mechanisms involved in their recognition of infected and tumor cells. In this paper we focus on Vγ9Vδ2 T cells, a major subset of human gamma delta T cells in blood and investigate the phosphoantigen-induced, MHCindependent molecular mechanisms governing their activation.
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(4, 7). pAgs bind directly to a positively charged pocket in the intracellular B30.2 domain of BTN3A1 (8, 9) . Other proteins important for pAg-induced T cell activation, such as RhoB GTPase and periplakin, are also reported to interact with the intracellular domain (10, 11) . Moreover, the BTN3A1 full-length intracellular domain (BFI), including the membrane proximal region located N-terminal to the B30.2 domain, undergoes a conformational change upon pAg binding (9) . However, it is unknown how exactly pAg binding triggers a conformational change of BFI and how this ultimately leads to Vγ9Vδ2 TCR engagement and T cell stimulation.
Here we present structural, biophysical, computational, and functional data dissecting the pAg-induced conformational change of the intracellular domain of BTN3A1. Using NMR spectrometry and molecular dynamics (MD) simulations, we show that the BTN3A1 B30.2 domain undergoes a global conformational change upon pAg binding. We also reveal two distinct dimer interfaces of the BFI domain through crystallography. Mapping residues with significant chemical shift perturbation (CSP), obtained by NMR, onto the crystal structure of BFI reveals changes across the B30.2 domain, many of which are located in the dimer interfaces. Together with additional supporting data from MD simulations, we propose that the binding of pAg induces changes in the dimer interface of the intracellular domain that can potentially propagate to the extracellular domain of BTN3A1. Combining approaches such as EM, cross-linking, and functional assays, we then demonstrate that the extracellular domains of BTN3A1 adopt a V-shaped conformation at rest. We further found that locking the extracellular domains in this resting conformation without perturbing their membrane reorganization properties diminishes pAg-induced T cell activation, suggesting that rearrangement of BTN3A1 proteins is critical to Vγ9Vδ2 T cell activation. Altogether, our data strongly support a model in which pAg-triggered conformational change of BTN3A1 is an essential molecular event leading to Vγ9Vδ2 T cell activation.
Results
pAg Induces a Global Conformational Change of the BTN3A1 Intracellular B30.2 Domain. Previous biophysical and structural studies have shown that pAgs bind directly to the BTN3A1 intracellular B30.2 domain (8, 9) . In our attempts to obtain B30.2-pAg complex crystals through ligand soaking we observed that B30.2 apo crystals dissolve upon pAg addition, hinting that pAg binding may cause conformational changes of the B30.2 domain which disrupt crystal packing (8) . To explore this possibility, we applied NMR techniques to the B30.2-pAg complex to reveal detailed structural information about the B30.2 domain upon pAg binding. Major CSP from multiple residues within the B30.2 domain were observed comparing the 15 N, 1 H-heteronuclear single quantum coherence (HSQC) spectra of 15 N-single labeled B30.2 with increasing concentrations of 1-hydroxy-2-methylpent-2-enyl-pyrophosphonate (cHDMAPP), kindly provided by C. Belmant, Innate Pharma, Marseille, France, a synthetic paralog to the naturally occurring microbial pAg 1-hydroxy-2-methylpent-2-enyl-pyrophosphate (HMBPP) (Fig. 1A) . The majority of these peaks exhibit fast-exchange behavior, whereas some peaks show intermediate to slow exchange behavior, suggesting a potential conformational change in addition to the ligand binding event. To understand where these CSPs reside on the 3D structure of the B30.2 domain, we performed 3D NMR spectroscopy for backbone resonance assignments of both B30.2 with and without pAg, using 2 H, 15 N, 13 C triple-labeled B30.2 protein sample. About 80% of the peaks appearing in the HSQC spectra were assigned, and the assigned residues covered almost the entire structure of B30.2 (Figs. S1 and S2). For residues with assignment in both apo and complex forms, we calculated the weighted average CSP of 15 N and 1 H between the free and pAg-bound B30.2 domain (Fig. 1B) . By mapping the residues undergoing large CSP (higher than SD) onto the crystal structure of B30.2 domain [Protein Data Bank (PDB) ID code 4N7I] we found that many of these residues are located near the pAg binding pocket, likely due to changes of the chemical environment in the presence of pAg (Fig. 1C) . Interestingly, there were several residues residing in remote sites away from the binding pocket, indicating that there is a nonlocal conformational change of B30.2 domain upon pAg binding (Fig. 1C) . Notably, some residues are either only assigned in apo or in pAg-bound form, likely due to the line-broadening effect from intermediate or slow chemical exchange (Fig. S2) . Interestingly, these residues reside mostly away from the pAgbinding pocket, again suggesting a conformational change distant from the pAg-binding pocket.
To further investigate the putative pAg-induced conformational change, we performed all-atom MD simulations of the BTN3A1 intracellular domain in the presence or absence of pAg cHDMAPP, starting from the crystal structure model. Rmsd backbone analysis of these simulations, which reveal structural shifts in the protein backbone over time, show that overall the crystal structure is stable in solution, with a mean deviation between crystal structure and simulation of 1.81 Å 2 for the apo systems and 1.57 Å 2 for the pAg-bound systems. Notably, singleresidue rmsd analysis of the backbone showed that the same residues that were identified in the CSP data accounted for the majority of this variation (Fig. 2A) . The specific residues showing the most prominent shifts in silico were along two distinct flexible loops encompassing residues 393-397 and residues 410-419. Visualization of these trajectories show that pAg keeps the binding pocket of the intracellular domain in a more contracted state, while the apo systems are free to adopt a more open, flexible conformation which gives atomic-level insight in to the pAg proximal chemical shifts outlined above (Fig. 2B) . Together, the NMR and computational data both strongly support the idea of a global conformational change of the B30.2 domain triggered by pAg binding. (Fig. 1B) . Because of its location near the pAg-binding pocket, we postulated that it might be important for pAg binding. To test this hypothesis, we used isothermal titration calorimetry (ITC) to measure the binding between the B30.2 alanine mutant of Y352 (Y352A) and both cHDMAPP and the weaker-potency, native pAg isopentenyl pyrophosphate (IPP). Previous ITC measurements have measured the affinities (dissociation constant, K d ) of these pAgs for the B30.2 domain to be ∼1 μM and ∼1 mM, respectively (8) . Compared with WT B30.2 protein, the mutant Y352A showed a significant defect in binding to both pAg species. In the case of cHDMAPP, the K d for the protein-ligand interaction exhibited a sixfold increase (weaker affinity) whereas the mutant interaction with IPP was undetectable ( Fig. 3A and Table S1 ). To determine if the Y352A mutant had similar effects on pAg-mediated Vγ9Vδ2 T cell activation, we transfected either full-length WT BTN3A1 or the Y352A mutant into HEK293 cells with the BTN3A genes (A1, A2, and A3) knocked out via CRISPRCas9 targeting. We then stimulated the Jurkat cells transduced with Vγ9Vδ2 G115 TCR by coculturing them with BTN3A1-transfected cells that were pretreated with either the microbial pAg HMBPP (the naturally occurring form of cHDMAPP) or the aminobisphosphate (NBP) pamidronate that causes intracellular IPP accumulation through inhibition of the enzyme farnesyl diphosphate synthase. Consistent with our biophysical measurements, the HMBPP-induced T cell activation was diminished for the Y352A mutant, but the defect was not as significant as the NBP-induced IPP activation, which was severely affected (Fig. 3B ). The 20.1 antibody (20.1 mAb)-elicited Vγ9Vδ2 response for the Y352A mutant was reduced compared with WT, but the difference was not statistically significant (Fig. 3B) . Together, these results indicate that residue Y352 in the B30.2 domain is critical for pAg binding. main. Crystals diffracted to 1.9 Å and the structure was refined to an R work /R free of 20.5%/23.4% ( Fig. 4A and Table S2 ). Unfortunately, the electron density for cHDMAPP was too weak to be interpreted unambiguously. However, the BFI crystalized in a different space group with two molecules in the asymmetric unit rather than one compared with the B30.2 domain structure published previously (8) . The dimer interface in the asymmetric unit, referred to as Dimer I hereafter, involves more than 20 residues from both monomers (Fig. 4B , Upper). Among these, the side chain hydroxyl group of Y352, the residue that undergoes the largest CSP and is critical for pAg binding and T cell activation (Figs. 1B and 3), is one of the major contributors to this dimer interface, making hydrogen bonds with the backbone of E327 and D328 from the other monomer ( Fig. 4B , Upper). Other important interface contacts are hydrophobic and van der Waals interactions made by W350, W391, and L471 from one monomer with a cluster of residues from the other monomer ( Fig. 4B , Upper). In addition to the Dimer I interface described above an additional dimer was identified, similar in orientation to that noted in the original B30.2 structure (PDB ID code 4N7I). In the BFI structure, the symmetrical N-terminal α-helical interface visualized in the original B30.2 domain structure is broken apart by the insertion of the membrane proximal region from residue K277 to S297. Unlike other parts of the membrane proximal region, this segment is well ordered in the BFI structure, clearly adopting an alpha helical structure. It interacts with the N terminus of the other monomer, mostly making hydrogen bonds and salt bridges, of which most are side-chain-specific (Fig. 4B, Lower) . This interface involving 28 residues is hereafter referred to as Dimer II.
Using MD simulations we probed the stability of these dimer forms. With the two BFI dimer interfaces as starting points for our simulations each system was equilibrated and then run at 293.15 K and 303.15 K until an accumulated total trajectory time of 0.5 μs was reached (simulation details are given in Materials and Methods). In the case of both interfaces, multiple contacts persist throughout the entire 0.5-μs trajectory, suggesting that both Dimer I and Dimer II are stable over this time period (Fig. 4B) . Visualizations of the simulated trajectories and analysis highlighting persistent contacts indicate that the hydrophobic interactions of the Dimer I interface and the interhelix hydrogen bonds and salt bridges of the Dimer II interface are both stable (Fig. 4B) . Therefore, combined evidence from crystallographic and MD simulation experiments suggest that BFI can adopt two dimer configurations.
The dimer configurations revealed in the BFI structure reveal interesting features upon further analysis. Intriguingly, the Dimer I interface is very close to the pAg-binding pocket (Fig. 4) . Moreover, in or near this dimer interface we also find a significant fraction of residues with major CSP or with differential assignments for the apo and the complex HSQC spectra. For example, Y352, a key residue in the Dimer I interface, showed the largest CSP as mentioned before (Fig. 1B) . In addition, among the residues buried in the Dimer I interface, residues L324, W350, H351, C353, K393, M394, and T395 experience significant changes in chemical environment (Fig. 4C, Left) . Notably, the same is true in the Dimer II interface for residues N300, L434, T438, S442, F443 and Y444 (Fig. 4C, Right) . This indicates that the pAg-induced conformation change is concentrated at these putative BFI dimer interfaces.
The Extracellular Domains of Full-Length BTN3A Adopt a V-Shaped Conformation in Lipid Nanodiscs. Since Vγ9Vδ2 T cells must detect signals on the extracellular side of target cells, the intracellular detection of pAg by BTN3A must be somehow transmitted to the extracellular space for detection. The conformation of the BTN3A extracellular domains has been speculated to be important for Vγ9Vδ2 T cell activation (6) . As mentioned earlier, the extracellular domains of BTN3A1 can adopt two alternative dimer conformations, namely a "V-shaped" form and a "head-to-tail" form, according to crystal structure models (PDB ID code 4F80) (6) . However, previous in vitro FRET assays on recombinant BTN3A1 extracellular domains provided evidence only for the existence of the V-shaped dimer (6) .
To fully examine the possibility of these two putative dimer conformations in a more physiologically relevant setting, we reconstituted full-length BTN3A dimers expressed in insect cells into nanodiscs, which are a synthetic model membrane system composed of a phospholipid bilayer surrounded by two amphipathic scaffold proteins (Fig. 5A) . Interestingly, although the expression level was equivalent, the purification process of BTN3A1/A2 heterodimer was much more successful than the BTN3A1 homodimers, leading to significantly higher yield of the protein product with greater stability (Fig. 5B and Fig. S3 ). For this reason, nanodiscs of the BTN3A1/A2 heterodimer, instead of the BTN3A1 homodimer, were visualized by negative-stain EM followed by single-particle analysis to examine the conformation of the extracellular domains in the context of full-length BTN3A dimers. Consistent with the previously published FRET data, the V-shaped conformation was readily observable in several 2D class averages (Fig. 5C ). In contrast, the head-to-tail conformation could not be unequivocally detected, even though the mean diameter of the reconstituted BTN3A dimer nanodisc is about 13 nm, which is large enough to accommodate the head-to-tail conformation (∼8 nm). We conclude that in the absence of other cellular components and/or exogenously added pAgs the extracellular domains of full-length BTN3A in a lipid bilayer form V-shaped dimers.
The Extracellular Domains of BTN3A1 in the Native Cellular Environment Adopt the V-Shaped Conformation at Rest. We next investigated whether the V-shaped conformation of BTN3A1 exists in the native cellular environment. To this end, we performed disulfide trapping by designing a pair of cysteine residues in BTN3A1 that should form an intermolecular disulfide bond if the protein adopts the V-shaped conformation (Fig. 6A) . Residues D124 and S207 in the V-shaped dimer interface were mutated to cysteines in the context of a mCherry-tagged full-length BTN3A1, and this construct was transfected into the BTN3A-KO HEK293 cells described previously. Cells expressing the engineered construct were either treated with the pAg HMBPP or left untreated and then subjected to flow cytometry to verify proper expression on the cell surface (Fig. S4) and Western blot analysis to detect dimerization (Fig. 6B) . As expected, all constructs appear as monomeric species when reducing agent is included in the protein-loading buffer to disrupt disulfide bonds (Fig. 6B, Upper) . However, under nonreducing conditions, which leave disulfide bonds intact, WT BTN3A1 appears as a monomer, whereas the D124/S207C mutant migrates as a homogenous high-molecular-weight species, with a molecular weight consistent with a BTN3A1 dimer (Fig. 6B, Lower) . Notably, dimerization of the D124/S207 was observed both with and without HMBPP treatment. These results demonstrate that BTN3A1 forms V-shaped dimers on the cell surface and are consistent with our in vitro data.
Locking BTN3A1 at the V-Shaped Dimer Interface Diminishes pAgInduced T Cell Activation. To test whether the conformation of the extracellular domains of BTN3A1 plays a role in pAg-induced T cell activation we assayed the disulfide-linked BTN3A1 mutant for its ability to stimulate Vγ9Vδ2 T cells in their basal state and upon addition of pAgs (HMBPP or NBP) or the 20.1 antibody. Intriguingly, we observed that locking BTN3A1 together at the V-shaped dimer interface (D124/S207C) significantly impaired both pAg-induced and 20.1-induced T cell activation (Fig. 6C ). This observation is consistent with the notion that the V-shaped conformation is the resting state of BTN3A1 and is not in itself sufficient for T cell activation. It has been reported previously that BTN3A1 becomes immobilized on the cell surface in the presence of 20.1 antibody, suggesting that BTN3A1 membrane reorganization is also important for Vγ9Vδ2 T cell activation (4). Thus, we speculated that the D124/S207C mutant might prevent T cell activation by disrupting proper immobilization of BTN3A1 on the cell surface. To formally test this prediction, we performed fluorescence recovery after photobleaching (FRAP) experiments, wherein mCherry-tagged BTN3A1 is photobleached within a small area of the cell surface and the recovery of fluorescence is observed as an indicator of BTN3A1 mobility within the membrane. Contrary to our prediction, we observed that the D124/S207C mutant exhibited no defect in immobilization in the presence of the 20.1 antibody (Fig.  6D and Fig. S5 ). This is evidence that even though important to Vγ9Vδ2 T cell activation, simply immobilizing BTN3A1 at the cell membrane is insufficient to stimulate Vγ9Vδ2 T cells. Based on the cumulative work presented here, we propose that the activation of Vγ9Vδ2 T cells requires additional features beyond membrane reorganization on the target cell, including a conformational rearrangement of the BTN3A1 extracellular domain.
Discussion
Human Vγ9Vδ2 T cell recognition of infection and tumorigenesis is of great interest in immunology and directly relevant for immunotherapeutic applications. Despite the significant potential of these cells, a clear understanding of the molecular mechanisms underlying pAg-induced T cell activation still remains elusive. The structural, biophysical, and functional data presented here provide insights into the events after intracellular pAg sensing critical for Vγ9Vδ2 T cell activation.
First, we showed by NMR spectrometry that upon pAg binding the BTN3A1 intracellular B30.2 domain undergoes a conformational change. A significant fraction of residues experiencing major CSP lie in or near the ligand-binding pocket but also include residues located in other regions of the B30. 2 of the intracellular domain monomer with and without pAg cHDMAPP provide insight into the structural changes that are causing these chemical shifts. Backbone rmsd analysis derived from the MD simulations are consistent with the NMR data and also suggest that the pAg-proximal CSPs, namely those of residues 393-397 and 410-419, are due to a decrease in flexibility of the binding pocket upon pAg binding. These backbone motions, which show overall flexibility in the apo simulations, can be seen in a relatively short (100 ns) timescale but do not rule out the possibility of slower, global changes in the protein backbone. Consistent with this idea, our NMR data revealed many residues exhibiting broadened signals either in the apo or the complex spectra possibly due to intermediate or slow chemical exchange, thus hindering their assignments of both spectra. Although these residues cannot be subjected to CSP analysis due to missing assignments and likely cannot be probed with all-atom MD simulations, they still reveal valuable information on where the chemical environment change occurs during ligand binding, and intriguingly, most are located remotely from the pAg-binding pocket (Fig. S2) .
What could be the main consequence of this conformational change? By mapping residues with major CSP and residues with differential assignments in the newly solved crystal structure of the BFI domain we found that many of these residues concentrated in two dimeric interfaces revealed in the structure. According to the MD simulations, the clusters of residues with major CSP and rmsd shifts reside in or near the Dimer I interface of the BFI. This overlap between interfacial residues and those that shift upon the addition of pAg, as well as the involvement of a residue required for pAg binding and T cell activation, Y352, further implicates a connection between pAg binding and intracellular conformational change (12) .
Y352 makes a major contribution to the Dimer I interface interaction through two hydrogen bonds via the hydroxyl group, and the contacts are shown to be long-lived (they persist for nearly the entire simulated trajectory). Based on the location of this residue in relation to the orientation of pAg in the binding site (8) , it might engage the isopentenyl chain of pAgs with its hydroxyl group, which could potentially compete with its dimer interface interactions. Indeed, Y352 experiences the largest CSP upon pAg binding, implying that its surrounding chemical environment changes substantially in the presence of pAg. These observations suggest that Y352 might act as a switch that directly links the pAg binding to the change of BTN3A1 intracellular domain dimer conformation. Since other residues within the same dimer interface also experience major change in their chemical environment in the presence of pAg, this pAg-sensing switch is likely to be a synergic effect among all these residues including Y352. This is consistent with our observation that single mutation of Y352 is not sufficient to completely abrogate the pAg-induced T cell activation.
The membrane proximal region of BFI is an important addition to the previously published B30.2 domain structure (8) . It is involved in a new, N-to N-terminal dimer interface (Dimer II) and adds stability to this particular interface based on the result from MD simulations. While the BFI interface is stable in simulation for the full 0.5-μs trajectory, the truncated B30.2 interface quickly dissociates (∼100 ns). Although we were unable to resolve the entire membrane proximal region in the crystal structure, previously published work from our laboratory and others suggests that this region interacts with other protein(s) that are important for pAg-induced T cell activation and may adopt a more structured conformation when bound to its partner(s) (10, 11) . Consistent with the idea that a conformational change likely occurs in this dimer interface, residues in this region were shown to undergo major CSP in previous studies (9) . Because of its location in between the intracellular and the extracellular domains, this region might be critical in translating the pAg-induced conformational change of BTN3A1 from inside to outside of the target cells, which could then be detected by Vγ9Vδ2 T cells. Structural determination of the full stem region with both apo and pAg-bound B30.2 domain could potentially reveal more detailed structural information on how this process would occur. How is a conformational change of the intracellular domain of BTN3A1 transduced to the extracellular region to be sensed by Vγ9Vδ2 T cells? A critical role of BTN3A extracellular domains in the activation process has been proposed, since the antibody 20.1 against the BTN3A extracellular domains can stimulate Vγ9Vδ2 T cells independent of pAgs. Two distinct dimer conformations, namely a V-shaped and a head-to-tail form, were observed in the crystal structure model of the BTN3A1 extracellular domains (6) . We originally speculated that the binding of 20.1 or binding of pAg in the BTN3A1 intracellular domain drives a conformation conversion between the two. Previous investigations of soluble versions of the BTN3A1 extracellular domains via FRET revealed evidence for only the V-shaped form (6). Here we examined the dimer conformations in the context of the full-length BTN3A1 protein in a reconstituted lipid system as well as in the native cellular environment. Consistent with our previous data, we found direct evidence for the existence of the V-shaped dimer form. The presence of the V-shaped extracellular domains in solution, in lipid-like nanodiscs, and in cellular membranes without any exogenously added pAg stimulants indicates that this form is a resting state of the BTN3A1 molecule. Furthermore, locking this dimer interface with engineered disulfide bonds produced BTN3A1 that is defective in its ability to mediate pAg-induced and 20.1-induced T cell activation. Interestingly, the Y352A mutant also showed a defect in both pAg-mediated and 20.1-mediated T cell stimulation. These results suggest that compromised dimer interfaces, either in the extracellular or the intracellular domains, can affect the global configuration of BTN3A1, and thus affect Vγ9Vδ2 T cell stimulation. We also assessed the membrane mobility of this mutant under different conditions using FRAP and found that it behaves much like the WT BTN3A1. Of note, in our FRAP analysis we were unable to observe a significant difference between PBS-treated and pamidronatetreated BTN3A1, both for the WT and the mutant BTN3A1 (Fig.  S5) . Since pAg-induced membrane reorganization was not impaired in the locked V-shaped mutant, these results suggest that even though membrane reorganization is important for pAg-induced T cell activation, itself alone is not sufficient to stimulate Vγ9Vδ2 T cells, and a conformational rearrangement of the extracellular domain is indeed critical for the activation process.
Outside of the crystallographic data where we observed the head-to-tail dimer we have no data supporting the existence or the functional relevance of this dimer in full-length, cell-surface expressed BTN3A. We originally speculated this could be the resting-state dimer. This is because the dimer interface of the head-to-tail dimer overlaps with the 20.1-binding site, and thus binding of the agonist 20.1 is incompatible with this dimer conformation and would presumably destabilize it on the cell surface (6) . However, the data presented here do not support the aforementioned hypothesis. Alternatively, based on the 20.1-BTN3A1 extracellular domain complex structure where we observed a subtle rotational shift in the V-shaped dimer when in complex with 20.1 (6), we hypothesize that a similar shift to BTN3A1 extracellular domains may be induced by pAg binding to the intracellular domain. This "rotational shift" model is consistent with the data we present here. Additional studies will be needed to determine whether such a state exists and, if so, to uncover the unique structural features that enable it to activate Vγ9Vδ2 T cells.
Overall, clarifying the nature of the BTN3A1 conformational change induced by pAgs is essential for understanding how an intracellular pAg-sensing event is transduced to outside of the target cells for possible detection by Vγ9Vδ2 T cells. Elucidation of the molecular mechanisms of pAg-induced T cell activation not only broadens and deepens our understanding of the myriad ways in which γδ T cells can be activated but also lays a foundation for practical applications such as the development of therapeutics targeting certain infectious diseases and cancers.
Materials and Methods
NMR Spectrometry. NMR spectra were acquired with Bruker AVANCE IIIHD 600-MHz NMR spectrometer equipped with a room-temperature TXI probe. All spectra were acquired on partially deuterated samples at a temperature of 25°C. It was found that at 600 MHz, HN transverse relaxation-optimized spectroscopy (TROSY) showed higher resolution than the normal HN HSQC. Assignments were thus obtained by analysis of TROSY versions of the standard triple resonance experiments including HNCO, HNcaCO, HNCA, HNCACB, HNcoCA, HNcoCACB, and NcocaNH. Spectra were processed in NMRpipe (12) and then assignments were done with CARA (13) . The average CSPs were calculated according to the formula ΔδNH = ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi ffi
for the residues assigned both in the free and ligand-bound B30.2 domain.
ITC.
Proteins samples for ITC were purified over a Superdex 200 into 20 mM Hepes, pH 7.4, and 150 mM NaCl. Concentration of peak fractions was determined from A 280 using the theoretical extinction coefficient. The fractions were pooled and diluted to 50 μM. IPP was obtained from Echelon Biosciences, and cHDMAPP was obtained from Innate Pharma. ITC data were collected using 50 μM B30.2 WT and Y352A mutant in the cell and 2 mM pAg in the syringe on a MicroCal iTC 200 (GE Healthcare Life Sciences) at 25°C using an initial injection of 0.4 μL followed by 19 2-μL injections. ITC binding fits were determined after reference subtraction of injections of the ligand into buffer only from the experimental results. Fits were determined using the Microcal Origin software. The stoichiometry (N) of the IPP-B30.2 interaction was set to one during fitting due to weak affinity.
Crystallization. Large rod-shaped crystals of apo BTN3A1 BFI were obtained using hanging drops consisting of 1 μL of 12.5 mg/mL protein purified as above with 4 mM β-mercaptoethanol in the protein solution and 1 μL of mother liquor containing 0.1 M Hepes, pH 7.0, 0.2 M MgCl 2 , and 22% PEG3350. Crystals were transferred into drops containing mother liquor with either an additional 1 mM, 5 mM, or 10 mM cHDMAPP and incubated at room temperature overnight. Of note, these crystals did not show any visible damage. Crystals were then cryoprotected by sequentially transferring to drops containing the mother liquor with an additional 5%, then 10%, and finally 20% glycerol before freezing. The cryoprotectant for each crystal contained 1 mM, 5 mM, or 10 mM cHDMAPP according to pAg-soaking condition of the crystal.
Data Collection and Processing. X-ray datasets for the BFI-pAg crystals were collected at the Advanced Photon Source (APS) beamline 23-ID-B on a MAR 300 CCD at 100°K. A complete dataset was collected over 360 images using a 0.5°oscillation at a wavelength of 1.033 × 10 −10 m. HKL2000 and Mosflm were used to index, integrate, and scale the data (14) . An initial molecular replacement solution was obtained using PHASER with PDB ID code 4N7I as a search model (15, 16 ). The initial model was built using ARP/wARP and improved using Coot with manual building followed by automated individual site, NCS, and B-factor refinement using Refmac5. All structural figures were generated using Pymol (DeLano Scientific).
All-Atom MD Simulations. All simulations performed were prepared using the CHARMM-GUI Input Generator (17) (18) (19) . All systems, starting from the BFI crystal structure, were fully hydrated with TIP3P water molecules and neutralized with 0.15 M KCl. All simulations were carried out in simulation boxes with periodic boundary conditions (20) using the additive PARAM36 force field from the CHARMM (Chemistry at HARvard Macromolecular Mechanics) (19) . pAg, which has not been parameterized and is not found in the BFI structure, was modeled in based on the binding location determined by Sandstrom et al. (8) with custom parameter files based upon other wellcharacterized diphosphate parameters. Simulation specifics varied for each system and are described in the SI Materials and Methods but used a combination of NAMD, OpenMM, and AMBER (18, (21) (22) (23) (24) . For all simulated systems run on the Midway Computing Cluster at the University of Chicago at least two replicas were run to confirm independence of results on initial velocity assignments.
BTN3A Nanodisc Production. Reconstitution of detergent-solubilized Histagged BTN3A1/A2 dimers was performed according to the protocols described by the Sligar laboratory with minor modifications (25) . BTN3A1/ A2 dimer was reconstituted into nanodiscs using either MSP 1D1 or E3D1 (Addgene) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC): TX-100 mixed micelles described in the SI Materials and Methods. Excess of detergent was removed by overnight incubation at 4°C with Bio-Beads SM-2 Adsorbents (Bio-Rad). BTN3A nanodiscs were separated from proteoliposomes and empty nanodiscs first by Ni-NTA resin pull-down (Qiagen) followed by Superdex 200 10/300 GL column (GE Healthcare) in 50 mM Hepes, pH 7.5, with 50 mM NaCl. As a control, empty nanodiscs were prepared using the same procedure. Gel filtration fractions corresponding to BTN3A1/ A2 nanodiscs were concentrated and an aliquot was shipped on ice to G.S. for negative-stain EM. The remainder sample was supplemented with 5% (wt/vol) sucrose, flash-frozen in liquid nitrogen, and stored at −80°C.
Negative-Stain EM. BTN3A1/A2 nanodiscs, produced as described above, were prepared for EM using the conventional negative staining protocol (26) and imaged at room temperature with a Tecnai T12 electron microscope operated at 120 kV using low-dose procedures. Images were recorded at a magnification of 71,138× and a defocus value of ∼1.5 μm on a Gatan US4000 CCD camera. All images were binned (2 × 2 pixels) to obtain a pixel size of 4.16 Å on the specimen level. Particles were manually excised using e2boxer (part of the EMAN 2 software suite) 200 (27) . Two-dimensional reference-free alignment and classification of particle projections was performed using ISAC (28); 4,359 projections of BTN3A1/A2 nanodisc were subjected to ISAC, producing 70 classes consistent over two-way matching and accounting for 3,968 particle projections.
In Vivo Cross-Linking. The BTN3A1 S207/D124C-RFP mutant cell lines were cultivated in a 150-mm TC-treated cell culture dish (Falcon) with 25 mL Dulbecco's modification of Eagle's medium media with 4.5 g/L glucose, L-glutamine, sodium pyruvate, and 10% FBS (Corning). The cells were either treated with 5 μM HMBPP (Sigma) for 2 h at 37°C or left untreated before harvesting using a large cell scraper (Corning). The cells were then washed three times with 1× PBS and incubated in PBS, pH 8.0, contained with 0.1 M iodoacetamide (Thermo Scientific) in the dark at room temperature for 30 min. After incubation, the cells were lysed and the plasma membrane (PM) fraction was isolated using the Minute PM protein isolation kit (Invent Biotechnologies, Inc.). The PM fraction was then split into two samples: one was treated with NuPAGE LDS sample buffer (Novex) supplemented with 600 mM β-mercaptoethanol and heated at 95°C for 5 min, and the other was treated with NuPAGE LDS sample buffer (Novex) alone without heating. All samples were then subjected to SDS/PAGE and Western blot analysis. The primary antibody used was a rabbit polyclonal antibody against residues 344-374 of BTN3A1 (LSBio) and the secondary antibody was a horseradish peroxidase-conjugated goat polyclonal antibody against rabbit IgG (EMD; Millipore). The blot was detected using SuperSignal West Pico chemiluminescent substrate (Thermo Scientific).
Functional Assays. For CD69 expression assays target cells were plated at 70% confluence in a 96-well plate (∼10,000 cells in total) and pretreated for 2 h at 37°C with either CD277-specific mAb (BioLegend) at 5 μg/mL, isotype control mAb (BioLegend) at 5 μg/mL, NBP pamidronate (Sigma) at 125 μM, or HBMPP (Sigma) at 5 μM per well. Treated cells were next extensively washed and cocultured together with Jurkat J.RT3-T3.5 T cells transfected with Vγ9Vδ2 G115 TCR (100,000 cells in total) at 37°C in complete RPMI-1640 Medium. G115 transductants alone treated with 1 μg/mL phytohemagglutinin (PHA) served as the positive control whereas transductants left untreated served as the negative control. After 4 h, cells were harvested, stained with fluorochrome-labeled Vδ2 TCR-specific mAb (BioLegend) and CD69-specific mAb (BioLegend) analyzed by flow cytometry. Data were collected on a Fortessa 4-15 or a LRII cytometer (BD Biosciences) and analyzed with FlowJo software (TreeStar). All of the experimental data were normalized to the positive control (100%) and the negative control (0%) using the following equation:
Normalized MFI = MFIðiÞ − MFIðnegative controlÞ MFIðpostive controlÞ − MFI ðnegative controlÞ × 100%, where MFI is the mean fluorescence intensity of each experimental group or the controls. More details are provided in SI Materials and Methods.
FRAP. mCherry-fused WT and D124/S207C mutant BTN3A1 transfected cells were cultivated and imaged in 35-mm, no. 1.5 coverslip, 10-mm glass-bottom dish (MatTek). The cells were subjected to pretreatment either with PBS, 250 μM pamidronate (Sigma), or 5 μg/mL purified anti BT3.1 20.1mAb (Biolegend) for 2 h at 37°C. Then the cells were imaged under Leica SP5II STED-CW supperresolution laser scanning confocal microscope (with 63×/1.4 UV oil objective). A 561-nm DPSS laser was used at 15% intensity for imaging and a 592-nm depletion laser was used at 80% intensity for photobleaching. The selected rectangular areas within the cell membrane were photobleached for five frames (200 ms per frame, 2-s interval). Images were collected every 5 s for 15 s (three frames, 200 ms per frame) before bleaching and every 2 s for 180 s (90 frames, 200 ms per frame) after bleaching. The images were processed using ImageJ software and the data were analyzed using PRISM6. More details are provided in SI Materials and Methods.
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